(Reuters) -Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients’ ability to exercise compared to standard-of-care treatment in a late-stage study.
The keenly watched drug, aficamten, significantly improved peak oxygen uptake, which was the study’s main goal, compared to metoprolol after 24 weeks of treatment, the company said.
The drug is being developed to treat obstructive hypertrophic cardiomyopathy, a condition that makes heart muscles stiff and can cause cardiac arrest.
Cytokinetics said it will present full results from the study at an upcoming medical meeting.
The drug had previously met the main goal in a separate late-stage study in 2023, where analysts said it showed favorable safety and efficacy compared to rival treatment Camzyos from Bristol Myers Squibb.
The U.S. Food and Drug Administration is set to decide on aficamten by December 26.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber and Shinjini Ganguli)
Brought to you by www.srnnews.com
